Health-related quality of life in women with breast cancer: A review of measures

To identify and describe the breast cancer–specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery).
Nội dung trích xuất từ tài liệu:
Health-related quality of life in women with breast cancer: A review of measuresSalasetal. BMC Cancer (2022) 22:66https://doi.org/10.1186/s12885-021-09157-w RESEARCH ARTICLE Open AccessHealth-related quality oflife inwomenwithbreast cancer: areview ofmeasuresMaribelSalas1,2*  , MargaretMordin3, ColleenCastro4  , ZahidulIslam1, NoraTu1and MichelleD.Hackshaw1  Abstract  Background:  To identify and describe the breast cancer–specific health-related quality of life (HRQoL) instruments with evidence of validation in the breast cancer population for potential use in patients treated for breast cancer (excluding surgery). Methods:  We conducted a systematic literature review using PubMed, Embase, and PsycINFO databases to identify articles that contain psychometric properties of HRQoL instruments used in patients with breast cancer. Relevant literature from January 1, 2009, to August 19, 2019, was searched. Articles published in English that reported psycho- metric properties (reliability, validity) of HRQoL instruments were identified. Results:  The database search yielded 613 unique records; 131 full-text articles were reviewed; 80 articles presented psychometric data for instruments used in breast cancer (including generic measures). This article reviews the 33 full articles describing psychometric properties of breast cancer-specific HRQoL instruments: EORTC QLQ-C30, EORTC QLQ-BR23, FACT-B, FBSI, NFBSI-16, YW-BCI36, BCSS, QuEST-Br, QLICP-BR, INA-BCHRQoL, and two newly developed unnamed measures, one by Deshpande and colleagues (for use in India) and one by Vanlemmens and colleagues (for use among young women and their partners). The articles that described the EORTC QLQ-C30, QLQ-BR23, and FACT-B centered on validating translations, providing additional support for content validity, and demonstrating acceptability of electronic patient-reported outcome administration. Psychometric properties of the measures were acceptable. Several new measures have been developed in Asia with an emphasis on development on cultural relevance/sensitiv- ity. Others focused on specific populations (i.e., young women with breast cancer). Conclusions:  Historically, there have been limited options for validated measures to assess HRQoL of patients with breast cancer. A number of new measures have been developed and validated, offering promising options for assess- ing HRQoL in this patient population. This review supports the reliability and validity of the EORTC QLQ-C30 and FACT- B; new translations and electronic versions of these measures further support their use for this population. Keywords:  PROMs, Breast cancerBackground or anyone else)” [1]. Patient-reported outcome measuresPatient-reported outcomes (PROs) are defined as a (PROMs) provide an opportunity for patients to indi-“measurement of any aspect of a patient’s health status cate the impact of a disease and its treatment on theirthat comes directly from the patient (i.e., without the lives. Health-related quality of life (HRQoL) representsinterpretation of the patient’s responses by a physician a patient’s physical, psychological, and social response to disease and therapy and is one type of PRO [2]. PROs can provide additional information to help with treat-*Correspondence: msalas@dsi.com1 Epidemiology, Clinical Safety andPharmacovigilance, Daiichi Sankyo, ment approval, reimbursement, and selection/dosingInc., 211 Mount Airy Road, 1A‑453, Basking Ridge, NJ 07920, USA decisions; management of medication side effects; healthFull list of author information is available at the end of the article monitoring; and patient-provider decision-making. © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creat​iveco​mmons.​org/​licen​ses/​by/4.​0/. The Creative Commons Public Domain Dedication waiver (http://​creat​iveco​ mmons.​org/​publi​cdoma​in/​zero/1.​0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Salasetal. BMC Cancer (2022) 22:66 ...